DRUG
Gonal-F®
225 to 450 IU/d; from day 2 of menstrual cycle onward
Status
Completed
Phase
Phase 4
Enrollment
129
Locations
1
Results
Not posted
Publications
0
Study summary
To overcome unsuitable effects of controlled ovarian hyperstimulation (COH )while maintaining large oocyte availability, investigators elaborated an innovative protocol (NATural Ovarian Stimulation) that dissociates E2 production from multiple follicle development. The purpose of this prospective, randomized trial is to demonstrate that, in a good prognosis IVF-ET population, the physiological E2 environment resulting from NATOS significantly improves IVF-ET outcome when compared to the conventional GnRH antagonist protocol.
Controlled ovarian hyperstimulation (COH) seeks to improve IVF-ET results by increasing per-cycle oocyte and embryo availability. Yet, the coexistence of multiple preovulatory follicles engenders compulsory alterations in the endocrine milieu of the follicular phase. The most evident of them are the extremely high serum estradiol (E2) levels. The 10 to 15-fold increase in E2 levels as a result of COH has been shown to provoke unwanted consequences in both embryo quality and uterine receptivity. Therefore, investigators elaborated an innovative COH protocol (NATural Ovarian Stimulation) that aimed at dissociating E2 production from multiple follicle development. To obtain this effect, they virtually curtailed endogenous LH production by using GnRH antagonist doses as strong and frequent enough to maintain E2 levels around the physiological range during standard exogenous FSH-only administration. Given that high E2 levels are commonly reached in patients having a normal follicle endowment, NATOS should target this group of good prognosis IVF-ET candidates. Indeed, this new COH approach was first tested in a pilot study that included 15 good prognosis IVF-ET candidates, aged 25-35 years, who volunteered to undergo NATOS. 11 out of 15 patients achieved a pregnancy. These pilot results spurred them to conduct a prospective, randomized trial to demonstrate that, in a good prognosis IVF-ET population, the physiological E2 environment resulting from NATOS significantly improves IVF-ET outcome when compared to the conventional GnRH antagonist protocol.
Interventions
DRUG
225 to 450 IU/d; from day 2 of menstrual cycle onward
DRUG
0.25 mg/day, starting on day 6 of Gonal-F®.
DRUG
1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
Timeline
First posted
Sep 8, 2016
Study start
Jan 13, 2017
Primary completion
Feb 8, 2019
Study completion
Feb 8, 2019
Results posted
Not reported
Registry updated
Apr 3, 2026
Outcomes
Live birth obtained after IVF-ET
Time frame · 1 month post-partum
Live birth defined as delivery ≥ 22 weeks of amenorrhea
Number of oocytes obtained
Time frame · At oocyte retrieval (14±8 days after start of treatment)
Eligibility
Inclusion Criteria: * IVF-ET candidates (excluding PGD and oocyte donor); * Body mass index from 18 to 30 kg/m2; * Non smokers; * Regular menstrual cycles (25-35 days); * Presence of both ovaries; * Antral follicle count (follicles measuring from 3 to 10 mm in diameter) ranging from 10 to 30 on cycle days 2 to 4; * Serum AMH levels ranging from 0.5 to 5.0 ng/mL; * Normal endometrium at ultrasound (US) and/or hysteroscopy; * Informed consent signed Exclusion Criteria: * Iatrogenic ovarian insufficiency (surgery, radiotherapy, chemotherapy); * Uterine abnormalities as demonstrated by pelvic US and/or hysteroscopy; * Usual contra-indications for COH (cancer risk, blood coagulation disorders, etc) * Renal insufficiency
Study locations
France. Showing up to 24 locations stored in the fast local snapshot.
Hôpital Antoine Béclère
Clamart, France
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Ahmed Saad · Poor Ovarian Reserve · Infertility (IVF Patients)
Phase 1 / Phase 2
Not yet recruiting
100
2026-07
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Infertility
Phase 3
Recruiting
266
2026-07
ART Fertility Clinics LLC · Ovarian Stimulation
Not applicable
Recruiting
150
2026-06
Bedaya Hospital · Infertility
Phase 2
Recruiting
120
2026-05
Beni-Suef University · IVF · PCO
Phase 2 / Phase 3
Completed
200
2026-04
Institut Cancerologie de l'Ouest · Breast Cancer
Phase 2
Active, not recruiting
102
2026-03
Fundación Santiago Dexeus Font · Infertility
Phase 4
Recruiting
120
2026-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.